A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
Clinical trial NCT05111249 · TERMINATED
Trial details
- NCT number
- NCT05111249
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-08
- Primary completion
- 2023-10-27
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.